The FDA has issued GRAS Letters of No Objection for Morinaga’s proprietary probiotic strain, Bifidobacterium breve M-16V.
November 5/Tokyo/Business Wire -- Morinaga Milk Industry Co. Ltd. announced that the U.S. FDA has issued Generally Recognized as Safe (GRAS) Letters of No Objection for Morinaga’s proprietary probiotic strain, Bifidobacterium breve M-16V for food applications and infant formulas.
The GRAS process is an FDA-recognized pathway that permits companies to have GRAS reviews carried out by independent panels of scientists, followed by GRAS determinations if an ingredient meets the FDA's criteria for safety. To ensure even greater confidence in its ingredients, Morinaga has submitted its safety dossiers to the U.S. FDA for review, which has resulted in these two Letters of No Objection.